Biodexa Pharmaceuticals (BDRX) Common Equity (2013 - 2025)
Biodexa Pharmaceuticals (BDRX) posted Common Equity of $15.2 million for Q4 2025, down 0.56% sequentially from $15.3 million in Q2 2025, and up 42.03% YoY from $10.7 million in Q4 2024.
Biodexa Pharmaceuticals (BDRX) Common Equity (2013 - 2025) Analysis & Trends
Biodexa Pharmaceuticals has reported Common Equity for 13 years, with the latest figure at $15.2 million in Q4 2025.
- Quarterly Common Equity rose 42.03% year-over-year to $15.2 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $15.2 million (up 42.03% YoY) and the FY2025 annual result came in at $15.0 million, up 40.78% from the prior year.
- Common Equity eased to $15.2 million in Q4 2025 per BDRX's latest filing, from $15.3 million in the prior quarter.
- Over five years, Common Equity peaked at $15.3 million in Q2 2025 and troughed at $3.7 million in Q4 2022.
- A 5-year average of $9.7 million and a median of $10.1 million in 2022 frame the typical range for Common Equity.
- The sharpest annual moves came in 2022 and 2024: Common Equity slumped 73.68% in 2022, then jumped 83.97% in 2024.
- Over 5 years, Common Equity stood at $14.1 million in 2021, then plunged by 73.68% to $3.7 million in 2022, then soared by 56.55% to $5.8 million in 2023, then soared by 83.97% to $10.7 million in 2024, then soared by 42.03% to $15.2 million in 2025.
- According to Business Quant data, Common Equity over the past three periods registered $15.2 million, $15.3 million, and $10.7 million for Q4 2025, Q2 2025, and Q4 2024 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 6.76 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 5.17 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 1.35 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 757.49 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 9.79 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 22.38 Bn |
| 10 | Biodexa Pharmaceuticals | 63,168.17 | -11.29 Mn | - | 15.17 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 15.17 Mn |
| Jun 30, 2025 | 15.26 Mn |
| Dec 31, 2024 | 10.68 Mn |
| Jun 30, 2024 | 11.02 Mn |
| Dec 31, 2023 | 5.81 Mn |
| Jun 30, 2023 | 6.63 Mn |
| Dec 31, 2022 | 3.71 Mn |
| Jun 30, 2022 | 9.43 Mn |
| Dec 31, 2021 | 14.09 Mn |
| Jun 30, 2021 | 5.24 Mn |
| Dec 31, 2020 | 8.87 Mn |
| Jun 30, 2020 | 5.65 Mn |
| Dec 31, 2019 | 25.15 Mn |
| Jun 30, 2019 | 31.84 Mn |
| Dec 31, 2018 | 21.78 Mn |
| Jun 30, 2018 | 31.84 Mn |
| Dec 31, 2017 | 46.04 Mn |
| Jun 30, 2017 | 47.04 Mn |
| Dec 31, 2016 | 56.85 Mn |
| Jun 30, 2016 | 58.50 Mn |